بحث بسيط
السجلات المعروضة 21 -- 30 من 34
Theranostic molecular profiling of pleomorphic ductal carcinoma of the breast.
(
Wiley
, 2019 , Other)
Pleomorphic ductal carcinoma (PDC) is a very rare subtype of invasive ductal carcinoma of no‐special type (NST), characterized by the presence of highly atypical/bizarre (>6‐fold variation in nuclear size) and multinucleated ...
The Role of Pathology in the Era of Personalized (Precision) Medicine: A Brief Review.
(
NLM (Medline)
, 2021 , Article)
This review provides a brief overview of the state-of-the-art molecular pathology approaches emphasizing the increasingly important pathology role in clinical precision cancer medicine. Recent advances in molecular biology ...
Nutm1-rearranged neoplasms: A heterogeneous group of primitive tumors with expanding spectrum of histology and molecular alterations: An updated review
(
MDPI
, 2021 , Article)
Nuclear protein of testis (NUT), a protein product of the NUTM1 gene (located on the long arm of chromosome 15) with highly restricted physiologic expression in post-meiotic spermatids, is the oncogenic driver of a group ...
An Update on the Molecular and Clinical Characteristics of Apocrine Carcinoma of the Breast
(
Elsevier
, 2021 , Article)
Apocrine carcinoma of the breast is a rare malignancy. According to 2019 WHO classification, apocrine cellular features and a characteristic steroid receptor profile (Estrogen receptor (ER)-negative and androgen receptor ...
HER2-positive apocrine carcinoma of the breast: a population-based analysis of treatment and outcome.
(
Springer
, 2022 , Other)
Apocrine carcinoma of the breast (APO) expresses HER2 in 30-50% of cases. This study explored the clinicopathological features and outcome of HER2+/APO and matched HER2+/NST cohort. We used the SEER database to explore the ...
Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy
(
Elsevier Ltd
, 2018 , Article)
Background: Cancer of unknown primary (CUP) accounts for approximately 3% of all malignancies. Avoiding immune destruction is a major cancer characteristic and therapies aimed at immune checkpoint blockade are in use for ...
PD-L1 testing by immunohistochemistry in Immuno-Oncology.
(
Association of Basic Medical Sciences of Federation of Bosnia and Herzegovina
, 2022 , Article Review)
Immunotherapy, based on immune checkpoint inhibitors targeting the Programmed cell death ligand 1 (PD-L1) and/or Programmed Death Receptor 1 (PD-1), has substantially improved the outcomes of patients with various cancers. ...
PD-L1 status in breast cancer: Current view and perspectives.
(
Elsevier
, 2019 , Article)
Breast cancer was traditionally not considered a particularly immunogenic tumor. However, recent developments have shown that some aggressive triple-negative breast cancers are immunogenic, exhibit a resistance to chemotherapy ...
Acinic cell carcinoma of the breast: A comprehensive review
(
Elsevier
, 2022 , Article)
Acinic cell carcinoma of the breast is a rare special subtype of breast cancer in the category of salivary gland-type tumors. It is morphologically similar to acinic cell carcinomas of salivary glands and pancreas and has ...
Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers
(
Association of Basic Medical Sciences of FBIH
, 2022 , Article)
Antibody-drug conjugates represent a new class of highly potent antineoplastic drugs built by attaching a small molecule of an anticancer drug (payload) or another therapeutic agent to an antibody recognizing an epitope ...